Toni K. Choueiri, MD
, director of the Lank Center for Genitourinary Oncology, director of the Kidney Cancer Center, senior physician at Dana-Farber Cancer Institute, and Jerome and Nancy Kohlberg Chair and professor of medicine at Harvard Medical School, discusses a recent clinical trial studying savolitinib, a MET-specific receptor tyrosine kinase (RTK) inhibitor, in patients with MET-driven papillary renal cell carcinoma (RCC).
Dr. Choueiri states a subset of approximately 30-40% of papillary RCC patients present with MET disruption or hepatocyte growth factor amplification. Although the phase 3 trial was ended prematurely due to an ongoing epidemiology study that found MET alteration was not prognostic for RCC treatment, initial results showed increased hazard ratios for progression free survival and overall survival, a higher response rate, and an improved toxicity profile when compared to the nonspecific RTK inhibitor sunitinib.
Learn more by clicking here